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The first cloned chain (IFNAR1) of the human interferon-a (IFNa) receptor acts as a species-specific transducer for type
I IFN action when transfected into heterologous mouse cells. Stably transfected mouse L929 cell lines expressing truncation
mutants of the intracellular domain of the human IFNAR1 chain were tested for biological responses to human IFNa. Deletion
of the intracellular domain resulted in a complete loss of sensitivity to the biological activity of human IFN but markedly
increased IFNAR1 cell surface expression, demonstrating that the intracellular domain is required for biological function and
contains a domain that negatively regulates its cell surface expression. Removal of the conserved membrane distal
16-amino-acid IRTAM (Interferon Receptor Tyrosine Activation Motif) sequence: (1) increased sensitivity to IFNa’s antiviral
activity, (2) increased the rapid IFNa-dependent formation of STAT-containing DNA-binding complexes, (3) prolonged tyrosine
phosphorylation kinetics of the JAK-STAT pathway, and (4) blocked the IFN-dependent down-regulation of the IFNAR1 chain.
These results indicate that the IRTAM negatively regulates signaling events required for the induction of IFN’s biological
actions via regulating receptor down-regulation. © 1998 Academic Press
INTRODUCTION
IFNa is a cytokine with antiviral, antiproliferative, and
immunomodulatory activities that binds to a multisubunit
cell surface receptor shared with IFNb (Branca et al.,
1982). The cloned components of the IFNa receptor, the
IFNa receptor 1 (IFNAR1) and the IFNa receptor 2 (IF-
NAR2) subunits, are required for high-affinity IFNa bind-
ing and the IFNa-dependent activation of the JAK1 and
TYK2 protein tyrosine kinases (Uze et al., 1990; Novick et
al., 1994; Domanski et al., 1995). IFN signaling to the cell
nucleus involves the Jak kinase-mediated tyrosine phos-
phorylation of the latent cytoplasmic STAT (signal trans-
ducers and activators of transcription) transcription fac-
tors. IFN-activated STAT1 and STAT2 translocate to the
nucleus, where they recognize the conserved IFN stim-
ulus response element (ISRE) within the promoter of
IFN-stimulated genes (ISGs), which is both necessary
and sufficient for ISG transcription (Schindler et al., 1992;
Fu, 1992). In addition, IFNa activates STAT3, which alone
or in combination with STAT1 forms sis-inducible factors
(SIFs) that bind to the c-sis-inducible element (SIE), orig-
inally described in the c-fos promoter (Wagner et al.,
1990).
The central importance of the IFNAR1 chain in the
function of the type 1 IFN receptor has been demon-
strated by the findings that the human IFNAR1 chain
undergoes rapid ligand-dependent tyrosine phosphory-
lation and acts as a species-specific transducer for type
I IFN action, and disruption of the IFNAR1 gene results in
the loss of the antiviral response to type I IFNs (Cleary et
al., 1994; Muller et al., 1994; Colamonici et al., 1994a,b;
Constantinescu et al., 1994. The intracellular domains of
type I IFN receptor chains contain conserved motifs that
likely function in transmembrane signaling (Constanti-
nescu et al., 1994; Mullersman and Pfeffer, 1994). The
intracellular domain of the human IFNAR1 (huIFNAR1)
chain contains a membrane distal motif, KYSSQTSQDS-
GNYSNE, which is perfectly conserved in the mouse and
bovine IFNAR1 chains (Uze et al., 1990, 1992; Mouchel-
Viehl et al., 1992) and which we refer to as the Interferon
Receptor Tyrosine Activation Motif (IRTAM). Within the
IRTAM are YSSQ and YSNE motifs which are potential
docking sites for SH2-containing downstream effectors.
These tyrosines are the only completely conserved ty-
rosine residues present in the intracellular domain of the
IFNAR1 chain, and their phosphoyrlation is required for
the IFN-dependent activation of STAT3 and PI3-kinase
(Yang et al., 1996; Pfeffer et al., 1997b).
To determine the role that the IRTAM of the huIFNAR1
chain plays in type I IFN signaling, truncation mutants of
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the huIFNAR1 chain were generated. Mouse L929 cell
transfectants expressing these mutant constructs were
isolated and assayed for their biologic response to hu-
man type I IFN. The results demonstrate the critical role
that the intracellular domain plays in IFN signaling and
specifically identify the carboxyl-terminal region of the
hulFNAR1 chain containing the IRTAM as an important
regulatory element in IFNa signaling pathways.
RESULTS
Isolation of murine cell lines expressing wild-type or
mutant constructs of the huIFNAR1 chain
In order to define the role of different domains of the
human IFNAR1 chain in the biological response to human
IFN, cDNAs encoding truncations in the intracellular do-
main of the huIFNAR1 were transfected into mouse L929
cells and stable cell lines were isolated. Figure 1 shows the
cell surface levels of mutant or wild-type human IFNAR1
chains on transfectants that were selected for further study.
Wild-type IFNAR1 and IFNAR1DIRTAM transfectants ex-
pressed similar levels of cell surface IFNAR1 chains (8000
sites/cell), while the IFNAR1DIC transfectant expressed ex-
tremely high levels of IFNAR1 chains ('150,000 sites/cell).
Therefore, removal of the intracellular domain markedly
increased IFNAR1 expression, while removal of the IRTAM
had no effect on expression, indicating that a domain lo-
cated membrane proximal to the IRTAM negatively regu-
lates cell surface receptor expresion.
The antiviral effect of human IFN on cells expressing
huIFNAR1 truncation mutant constructs
Since by definition IFNs inhibit viral replication, we
determined the antiviral sensitivity to human IFN of
murine cells expressing the various constructs of the
huIFNAR1 chain. As shown in Fig. 2 and consistent
with previous studies (Colamonici et al., 1994b; Con-
stantinescu et al., 1995; Pfeffer et al., 1997a), murine
cells expressing the wild-type huIFNAR1 chain are
sensitive to the antiviral effects of human IFNcon1 and
IFNa8 on VSV replication. The antiviral effect in wild-
type huIFNAR1-expressing transfectants exhibited a
clear dose-dependence, with IFNcon1 showing a
slightly higher antiviral activity than IFNa8 at all IFN
concentrations examined. In contrast, cells trans-
fected with the empty pLXSN vector of the IFNAR1DIC
mutant were resistant to the antiviral action of human
IFN, with little antiviral activity observed even with
10,000 IU/ml of human IFN. This result demonstrates
the requirement for the intracellular domain of the
huIFNAR1 chain to transduce the signal initiated at the
receptor.
In contrast, cells transfected with the IFNAR1DIRTAM
were more sensitive to the antiviral action of human
IFNcon1 or IFNa8 when compared to cells expresing
the wild-type huIFNAR1 chain, although the cell sur-
face levels of the truncated receptor IFNAR1DIRTAM
and wild-type huIFNAR1 were equivalent. For example,
at an IFN concentration of 100 IU/ml there were 27.5
and '22-fold increases in the antiviral activity of IFN-
con1 and IFNa8, respectively, in cells expressing the
IFNAR1DIRTAM relative to the wild-type transfectants
(Fig. 2). However, all transfected cell lines supported
viral replication to similar extents (VSV titers between
1 and 3 3 108 PFU/ml), which argues against the
differences in IFN sensitivities in the various transfec-
tants being due to clonal variation.
FIG. 1. Schematic diagram of truncation and point mutants of the huIFNAR1 constructs. The extracellular, transmembrane, and intracellular
domains, as well as the two tyrosine residues in the IRTAM, are indicated. The number of huIFNAR1 chains in each transfectant was determined by
binding assays performed with 125I-labeled anti-huIFNAR1. The results of two separate assays on at least two independent transfectants performed
in duplicate were averaged (SEM , 15%).
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IFN-dependent formation of STAT-containing ISGF3
and SIF complexes in cells expressing huIFNAR1
truncation mutants
Since removal of the IRTAM enhanced sensitivity to
IFN’s antiviral action, we examined the effect of the
IRTAM’s removal on the activation of the DNA-binding
activity of STAT proteins. The IFN-induced activation of
STAT1 and STAT2 in nuclear extracts of IFNcon1-treated
transfectants was determined by ISGF3 formation in gel
shift assays. As shown in Fig. 3A, ISGF3 activity was
detectable in both wild-type huIFNAR1 and IFNAR-
1DIRTAM transfectants following stimulation of cells with
IFNcon1 for 30 min, was maximal at 2 h, and declined by
6 h. However, the ISGF3 activity was greater in the
IFNAR1DIRTAM transfectants ('7.5- and 16-fold by quan-
titation of phosphorimages at 2 and 4 h, respectively). In
contrast, IFN treatment did not induce ISGF3 formation in
cells expressing the IFNAR1DIC or in cells transfected
with the empty vector (Fig. 3B).
IFN treatment also activates SIF complexes (contain-
ing STAT1 and STAT3) which bind to the SIE present in
various cytokine-regulated genes (Yang et al., 1996).
Since the pathways that result in the formation of ISGF3
and SIF complexes may be differentially regulated, we
determined IFN-induced SIF formation in each of the
mutant huIFNAR1 expressing cell lines. Figure 4A shows
SIF formation at times varying from 0 to 24 h following
IFNcon1 addition to wild-type huIFNAR1 transfectants,
as assayed in gel shift assays with a labeled SIE oligo-
nucleotide probe. A low basal level of SIF complexes
was evident in untreated cells, which is in contrast to the
failure to detect any basal levels of ISGF3 in the same
cells. At 30 min following IFN stimulation SIF complexes
FIG. 2. The effects of human IFN on VSV replication in murine cells expressing wild-type or truncation mutants of the huIFNAR1 chain. Transfectants
were treated for 18 h with IFNcon1 (A) or IFNa8 (B). IFN-treated cells were infected with VSV, and 24 h later the virus yield in the medium was assayed
by plaque formation. The results of three separate experiments were averaged (SEM , 20%) and expressed as the VSV titer produced. EV, empty
vector transfectant.
FIG. 3. IFN-induced ISGF3 formation in murine cells expressing
truncation mutants of the huIFNAR1 chain. (A) Murine transfectants
expressing the wild-type or the IFNAR1DIC construct (DIC) were
treated with IFNcon1 (10,000 IU/ml) for times indicated prior to gel shift
analysis with an ISRE probe. A representative result from three sepa-
rate experiments is shown. (B) Murine L929 cells transfected with
empty vector (EV), wild-type huIFNAR1 (WT), the IFNAR1DIC construct
(DIC), or the IFNAR1DIRTAM (DIRTAM) were treated with IFNcon1
(10,000 IU/ml) for 30 min prior to gel shift analysis with an ISRE probe.
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were induced to near maximal levels, and they remained
elevated at 2 h. During this time period the levels of SIF
formation were greater in cells expressing the IRTAM
deletion. The STAT compositions of the SIF complexes
have been previously demonstrated by supershift assays
(Yang et al., 1996) to be STAT3 dimers (SIF-A), STAT1-
STAT3 heterodimers (SIF-B), and STAT1 dimers (SIF-C). A
higher IFN-dependent induction of all three SIF com-
plexes was observed in the IFNAR1DIRTAM transfec-
tants relative to the wild-type huIFNAR1-expressing cells
('5- to 8-fold by quantitation of phosphorimages at 0.5
and 2 h, respectively). In contrast, the low basal level of
SIF activity detected in the empty vector and IFNAR1DIC
transfectants did not increase following IFN stimulation
(Fig. 4B).
Prolonged activation of the JAK-STAT pathway in cells
expressing IFNAR1DIRTAM
The induction of ISGF3 and SIF DNA-binding activity
reflects the IFNa-dependent activation of the JAK1 and
TYK2 protein tyrosine kinases and the Jak kinase-medi-
ated tyrosine phosphorylation of STAT transcription fac-
tors. Since the levels of ISGF3 and SIF formation were
greater in cells expressing the IRTAM deletion, we ex-
amined the IFN-dependent tyrosine phosphorylation of
the TYK2 Jak kinase and the STAT2 transcription factor in
wild-type and IFNAR1DIC transfectants. As shown in Fig.
5 TYK2 and STAT2 tyrosine phosphorylation was detect-
able in both wild-type huIFNAR1 and IFNAR1DIRTAM
transfectants following stimulation of cells with IFNcon1
for 30 min. However, the levels of tyrosine phosphoryla-
tion of TYK2 and STAT2 were greater (;8- to 10-fold by
quantitation of autoradiograms at 0.5 h) in the
IFNAR1DIRTAM transfectants. Furthermore, the tyrosine
phosphorylation of TYK2 and STAT2 persisted for longer
times (greater than 6 h) after IFN treatment in the
IFNAR1DIRTAM transfectants when compared to wild-
type IFNAR1 transfectants (not detectable by 6 h for TYK2
and by 4 h for STAT2).
Impaired down-regulation of IFNAR1 in cells
expressing IFNAR1DIRTAM
Since down-regulation of receptor subunits is a pri-
mary mechanism to terminate signal generation, we ex-
amined if the increased IFN sensitivity in IFNAR1DIRTAM
transfectants reflected an impaired IFN-induced IFNAR1
down-regulation. IFN treatment (3 h) down-regulates
'80% of the IFNAR1 chain in human cells and '50% of
huIFNAR1 chains in mouse cells expressing human IF-
NAR1 chain (Constantinescu et al., 1994). In the present
study, the level of surface IFNAR1 in cells expressing the
wild-type IFNAR1 and IFNAR1DIRTAM was determined
following IFN treatment (3 h). Table 1 shows that IFN
down-regulated .40% of huIFNAR1 chains in cells ex-
pressing wild-type IFNAR1 and in WA-17 mouse cells
expressing three copies of the IFNAR1-encoding human
FIG. 4. IFN-induced SIF complex formation in murine cells express-
ing truncation mutants of the huIFNAR1 chain. (A) Murine transfectants
expressing the wild-type or the IFNAR1DIC construct were treated with
IFNcon1 (10,000 IU/ml) for times indicated prior to gel shift analysis
with an SIE probe. A representative result from three separate exper-
iments is shown. (B) Murine transfectants described in Fig. 3 were
treated with IFNcon1 (10,000 IU/ml) for 2 h prior to gel shift analysis
with an SIE probe.
FIG. 5. IFN-induced tyrosine phosphorylation of TYK2 and STAT2 in murine cells expressing truncation mutants of the huIFNAR1 chain. Cell lysates
were prepared from murine transfectants expressing the wild-type or the IFNAR1DIC construct treated with IFNcon1 (10,000 IU/ml) for times indicated.
Lysates were immunoprecipitated with anti-TYK2 (A) or anti-STAT2 (B). The proteins were resolved by SDS–PAGE, blotted onto PVDF membranes,
probed with anti-pTyr, and visualized by enhanced chemiluminescence (Amersham).
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chromosome 21. In contrast, no IFN-induced down-reg-
ulation of IFNAR1 chains was observed in the IFNAR1-
DIRTAM transfectants.
DISCUSSION
Previous studies have established that the IFNAR1
chain plays a critical role in signal transduction by IFNa.
Within minutes of IFNa exposure, the huIFNAR1 chain
undergoes tyrosine phosphorylation (Constantinescu et
al., 1994), thereby providing phosphotyrosine docking
sites for SH2 domain-containing cytoplasmic effectors.
The intracellular domain of the huIFNAR1 chain has four
potential tyrosine phosphorylation sites, which are ap-
portioned equally into two intracellular subdomains: (1) a
membrane proximal 50-amino-acid motif common to
other signal transducing chains of the type II cytokine
receptor family (Mullersman and Pfeffer, 1994), contain-
ing the docking site for TYK2 (Colamonici et al., 1994a;
Yan et al., 1996b) and STAT2 (Yan et al., 1996a); and the
carboxy-terminal 16-amino-acid IRTAM with the only com-
pletely conserved tyrosine-based motifs in the huIFNAR1.
To define the role of the IRTAM in the biological func-
tion of IFNAR1, cell lines stably expressing various IF-
NAR1 truncation mutants were isolated. Consistent with
previous studies, transfection of wild-type huIFNAR1 into
mouse L929 cells made them sensitive to the antiviral
and gene-inducing activities of human IFN, although
L929 cells are intrinsically resistant to human IFN
(Colamonici et al., 1994b; Constantinescu et al., 1994;
Pfeffer et al., 1997a). Most importantly, removal of the
IRTAM increased responsiveness to human IFN, indicat-
ing that the IRTAM plays a negative regulatory role in IFN
signaling. For example, the antiviral activity of human
IFNcon1 and IFNa8 was greatly enhanced in mouse
cells expressing the IFNAR1DIRTAM mutant of the IF-
NAR1 chain, when compared to cells expressing wild-
type huIFNAR1. Furthermore, the levels of IFN-induced
ISRE- and SIE-dependent gel shift activity were consis-
tently greater in the IFNAR1DIRTAM transfectants than in
the wild-type transfectants. These results are in agree-
ment with the recent finding that removal of the IRTAM
results in increased HLA class I induction and ISGF3
formation in murine transfectants expressing human IF-
NAR1 constructs (Gibbs et al., 1996).
Furthermore, we provide evidence that the IRTAM can
act as a negative regulatory domain, presumably by
affecting receptor down-regulation. For example, we
found that although IFN treatment (10,000 IU/ml for 3 h)
down-regulated huIFNAR1 chains in wild-type transfec-
tants, there was no detectable IFN-dependent down-
regulation of the huIFNAR1 chain in the IRTAM truncation
mutant. Blockage or delay of IFN-dependent down-reg-
ulation of the IFNAR1 chain would allow signals initiated
by ligand binding to persist. Although we cannot exclude
other mechanisms whereby the IRTAM can act as a
negative regulatory domain (by steric hindrance, by act-
ing as a pseudosubstrate, or by binding a tyrosine phos-
phatase), removal of the IRTAM enhanced IFN-depen-
dent biological activities.
We also show that while the IFNAR1DIRTAM is biolog-
ically active, there is a complete loss of biologic activity
in cells expressing a truncation of the huIFNAR1 intra-
cellular domain. These results indicate that there are
functionally important sequences in the intracellular do-
main of IFNAR1 between the transmembrane region and
the membrane distal IRTAM. This is consistent with the
fact that TYK2 and STAT2, both primary mediators of the
type I IFN response, associate with the membrane prox-
imal region of the huIFNAR1 chain (Colamonici et al.,
1994a; Yan et al., 1996a,b). Since deletion of the IRTAM
leads to a heightened sensitivity of murine transfectants
to human IFN, important signaling molecules that primar-
ily dock to the IRTAM of huIFNAR1 may also bind to
alternative sites. For example, the YSSQ and YSNE motifs
in the IRTAM of huIFNAR1 that bind STAT3 are also
present in the murine IFNAR1 chain (Pfeffer et al., 1997b).
A YDDE motif (similar to the YSNE motif of the IRTAM) is
present in the intracellular domain of the four cloned
homologues of the full-length IFNAR2 chain (human, bo-
vine, murine, and ovine). In addition, membrane proximal
tyrosine residues (Y466 and Y481) of IFNAR1 may also
serve as secondary docking sites for IFN-signaling mol-
ecules.
The antiviral response in the various huIFNAR1 trans-
fectants directly correlated with the formation of STAT-
containing DNA–protein complexes. While an increased
antiviral activity of human IFN was observed in the
IFNAR1DIRTAM transfectant in which an increased for-
mation of IFN-dependent gel shift activities was also
observed, the IFNAR1DIC transfectant did not respond to
the antiviral action of human or to induction of ISRE- or
SIE-dependent DNA–protein complexes. The role that
IFN-induced proteins encoded by ISRE-controlled genes
(Mx proteins, double-stranded RNA-dependent protein
kinase, and 2,5-oligoadenylate synthetase) play in the
antiviral effects of IFN are well documented. The role that
SIF complexes play in IFN responses is unknown. How-
TABLE 1






WA-17 cell line 4200 46.3 6 4.1
Wild-type IFNAR1 transfectant 8000 42.5 6 2.6
IFNAR1DIRTAM transfectant 8000 0.5 6 1.6
Note. Cells were treated for 3 h with IFNcon1 (10,000 IU/ml) and then
the level of IFNAR1 expression was determined as described under
Materials and Methods. Controls received no IFN. The results of four
separate experiments were averaged.
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ever, since the SIE resembles the GAS element originally
described in the promoters of IFNg-stimulated genes,
SIF complexes might mediate the transcription of a sub-
set of IFNa-regulated genes which contain GAS ele-
ments, such as the IRF-1 transcription factor which is
required for the antiviral action of IFN (Pine, 1992; Pine et
al., 1994).
In this report, we attempted to disentangle positive
versus negative regulatory signals transduced through
the IFNAR1 chain of the IFNa/b receptor. We separated
changes in signaling due to differences in cell-surface
expression (IFNAR1DIC) from effects due to more subtle
alterations of IFNAR1 (IFNAR1DIRTAM) which do not
modify the constitutive levels of expression. Our results
suggest that the highly conserved 16-amino-acid IRTAM
of huIFNAR1 chain transduces negative regulatory sig-
nals through the IFNa receptor by promoting IFN-in-
duced IFNAR1 down-regulation. Removal of the IRTAM
increased sensitivity to the antiviral activity of IFNa, in-
creased the rapid IFNa-dependent tyrosine phosphory-
lation of TYK2 and STAT2, and increased the rapid IFNa-
dependent formation of DNA–protein complexes that
contain STAT1, STAT2, and STAT3.
MATERIALS AND METHODS
Interferons and monoclonal antibodies
The activity of recombinant human IFNcon1 (1 3 109
IU/mg) and IFNa8 (2 3 107 IU/mg) was assayed by
protection against the cytopathic effect of vesicular sto-
matitis virus (VSV) on human fibroblasts and expressed
in international reference units (IU/ml) using the NIH
human IFNa standard for reference. The 4B1 MoAb di-
rected against the extracellular domain of the huIFNAR1
chain has been previously described (Constantinescu et
al., 1994).
Cell culture and generation of stable transfectants
Mouse L929 fibroblasts were maintained in Dulbec-
co’s modified Eagle’s medium supplemented with 10%
(v/v) heat-inactivated bovine calf serum. Stable cell lines
expressing the mutant constructs described were gen-
erated by liposome-mediated transfections. Plasmid
DNA (9 mg) mixed with 54 ml of Lipofectamine (Life
Technologies, Gaithersburg, MD) was added to 5 3 105
cells per 25-cm2 flask. Transfected cultures were refed
24 h later and, after an additional 3 days, selected in
medium containing 1.5 mg/ml G418 (Life Technologies).
After 7 to 10 days, clones were isolated by limiting
dilution.
Generation of truncation mutants of the huIFNAR1
chain
The huIFNAR1 truncation mutants were generated
by PCR-mediated mutagenesis of p23 (American Type
Culture Collection, Rockville, MD), which contains the
IFNAR1 cDNA in pBluescript (SK2) (Uze et al., 1990).
The intracellular truncation mutant IFNAR1DIC con-
tained the complete extracellular and transmembrane
domains and the first four residues of the intracellular
domain to allow its anchorage in the plasma mem-
brane. To generate IFNAR1DIC, PCR primers 59-TT-
GAGTGAGTGAC-39 and 59-TCGAGTCACTCACTCAAT-
GCA-39 were annealed to generate a cassette encod-
ing a stop codon in all three reading frames flanked by
NsiI- and XhoI-compatible ends. PCR reactions in-
cluded 1 mM each primer, 100 mM each dNTP, 50 ng of
p23, and 2.5 U of PFU polymerase in a 50-ml reaction
volume. Fifteen amplification cycles were performed at
94°C for 1 min, 65°C for 1 min and 72°C for 2 min. The
cassette was then cloned into the p23 IFNAR1 cDNA
digested with NsiI (nucleotide 1460 of the huIFNAR1
cDNA) and XhoI (present in the vector on the 39 side of
the cDNA). The huIFNAR1 mutant depleted of the IR-
TAM (IFNAR1DIRTAM) was generated by PCR using
primers 59-GCTGTATGTGAGAAAACAAAACCAGG-39
and 59-CTCGAGTCATTCTTCTACTGTAGCAATTGTGC-
39. The NsiI/XhoI-digested PCR product was cloned
into the NsiI/XhoI-digested p23, replacing nucleotides
1348–2784 of the wild-type huIFNAR1 with the PCR
product representing nucleotides 1348 through 1620.
Constructs were sequenced using the dideoxy method
(Sequenase; United States Biochemicals, Cleveland,
OH) and cloned between the EcoRI and XhoI sites of
the retroviral pLXSN vector (Miller et al., 1993).
Analysis of huIFNAR1 expression by binding
of I125-labeled anti-IFNAR1 antibody
Cell lines expressing the transfected huIFNAR1 chains
were screened by the binding of I125-labeled 4B1 anti-
huIFNAR1 MoAb as previously described (Constanti-
nescu et al., 1994). The number of huIFNAR1 chains
expressed in each murine transfectant was determined
by Scatchard analysis of the binding data. For down-
regulation studies, cells were seeded at 2 3 105 cells per
2.1-cm2 well (Constantinescu et al., 1995). The next day,
cells were treated for 3 h with 10,000 IU/ml IFNcon1, and
the level of cell surface IFNAR1 chains was determined
with I125-labeled anti-huIFNAR1.
Antiviral assays
The antiviral activity of human IFNs was measured by the
inhibition of VSV replication in mouse cells (Improta et al.,
1992). Transfectants (5 3 106 cells per 25-cm2 flask) were
treated with IFN for 1 day and then infected at 0.1 plaque-
forming unit (PFU)/cell of VSV for 2 h. At 24 h postinfection,
virus production was assayed by plaque formation on Vero
indicator cells (Pfeffer et al., 1990).
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Gel shift assays
For gel shift analysis, equivalent amounts of the nuclear
extracts prepared as previously described (Yang et al.,
1996) were incubated with a 32P-labeled promoter probe for
either the high-affinity SIE from the c-fos gene (59-GTCGA-
CATTTCCCGTAAATC-39) or the ISRE from ISG15 (59-
GATCGGGAAAGGGAAACCGAAACTGAAGCC-39) at 20°C
for 20 min, and the free probe was separated from protein–
DNA complexes on 5% polyacrylamide gels.
Immunoprecipitations and immunoblot analysis.
For immunoprecipitation studies, cultures were
washed with ice-cold PBS and lysed for 20 min in lysis
buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5
% NP-40; 15% glycerol) containing 1 mM NaF, 1 mM
Na3VO4, 1 mM PMSF, 5 mg/ml soybean trypsin inhibitor,
5 mg/ml leupeptin, and 1.75 mg/ml benzamidine (Fu,
1992). Samples were centrifuged (12,000 g, 15 min) at
4°C and supernates were immunoprecipitated with anti-
TYK2 or -STAT2 Ab (Santa Cruz Laboratories) overnight at
4°C. Immune complexes were collected using Protein
A–Sepharose beads (Pharmacia) and eluted in sample
buffer. Samples were run on SDS–7.5% PAGE, transferred
to PVDF membranes (Millipore), and probed with anti-
phosphotyrosine (anti-pTyr, Oncogene Sciences Ab-2)
(dilution 1:1000), followed by anti-mouse IgG coupled
with horseradish peroxidase (Amersham). Blots were
developed using enhanced chemiluminescence (ECL,
Amersham).
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